DEBRA Research Invests in Nova Anchora for Advancing Epidermolysis Bullosa Therapy

DEBRA Research GmbH has announced an impact investment in Nova Anchora to advance protein therapy for Epidermolysis bullosa (EB). Other investors include Viking Global Investors, CureEB, EBMRF, and Stanford University. This financing will push forward Nova Anchora's lead candidate, NvA-011, a recombinant collagen therapy, through essential preclinical and IND-enabling studies.

Nova Anchora, established in 2021 in San Francisco, is tackling dystrophic Epidermolysis bullosa (DEB), a severe form of the disorder. Using technology from Stanford University, NvA-011 aims to correct defective type VII collagen topically. The investment also sets the stage for a Series A financing round to begin clinical trials.

The collaboration signifies a unified effort to improve EB treatments. DEBRA Research's Managing Director, Dr. Martin Steiner, highlighted the synergy of philanthropic and venture capital efforts in pioneering innovative therapies for EB patients.